Daiichi Sankyo Company, Limited · TSE:4568
Daiichi Sankyo — Q3 FY2018 Earnings Presentation
37 slides from Daiichi Sankyo's earnings presentation, Jan 31, 2019
Slide 1: FY2018 Q3 Financial Results Presentation
FY2018 Q3 Financial Results Presentation DAIICHI SANKYO CO., LTD Toshiaki Sai Executive Vice President and CFO January 31, 2019
Slide 2: Forward-Looking Statements
Forward-Looking Statements Management strategies and plans, financial forecasts, future projections and policies, and R&D information that Daiichi Sankyo discloses in this material are all classified as Daiichi Sankyo’s future prospects. These forward looking statements were determined by Daiichi Sa
Slide 3: Agenda
Agenda FY2018 Q3 Financial Results Business Update Edoxaban Regional Value Optimizing Supply Chain R&D Update 3
Slide 4: FY2018 Q3 Financial Results
FY2018 Q3 Financial Results 4
Slide 5: Overview of FY2018 Q3 Results
Overview of FY2018 Q3 Results (Bn JPY) FY2017 Q3 YTD FY2018 Q3 YTD YoY Results Results -5.1% Revenue 741.0 703.1 -38.0 Cost of Sales 255.5 264.9 +9.5 SG&A Expenses 216.7 198.5 -18.2 R&D Expenses 175.6 142.6 -33.0 +4.1% Operating Profit 93.2 97.1 +3.9 Profit before Tax 97.7 98.0 +0.2 Profit attributa
Slide 6: Revenue
Revenue Decreased by 38.0 Bn JPY (Decreased by 36.5 Bn JPY excl. forex impact) (Bn JPY) Positive Factors Negative Factors FY2017 Results Japan 741.0 Lixiana +14.6 Olmetec -28.5 Japan Pralia +3.7 Nexium -9.0 (incl. vaccines, 24.9 Inavir -4.8 OTC-related) Loxonin -4.7 (Incl. impact of price revision i
Slide 7: Operating Profit
Operating Profit Increased by 3.9 Bn JPY (Decreased by 23.4 Bn JPY excl. forex impact and special items) FY2017 Results 93.2 増益 減益 (Bn JPY) Revenue -38.0 Revenue 38.0 incl. forex impact of -1.5 Cost of Sales 3.8 Cost of Sales +3.8 (Cost increased) Product mix due to impact of olmesartan LOE SG&A Exp
Slide 8: Special Items
Special Items (Bn JPY) FY2017 Q3 YTD FY2018 Q3 YTD YoY Results Results Cost of Sales Gain on sales of fixed assets -6.1 +6.1 SG&A Expenses Gain on sales of fixed assets -3.5 -3.5 R&D Expenses Impairment loss (Intangible) 30.2 -30.2 Total 24.1 -3.5 -27.6 - : Cost decreased items * No items booked in
Slide 9: Profit Attributable to Owners of the Company
Profit Attributable to Owners of the Company Increased by 6.2 Bn JPY FY2017 Results 72.6 (Bn JPY) Financial Income/ +3.7 (Cost increased) Operating Profit 3.9 Expenses etc. Deterioration of forex gains/ losses Financial Income/ Expenses etc. 3.7 Income Taxes etc. -6.5 (Cost decreased) Impact of the
Slide 10: Revenue: Major Business Units (incl. Forex Impact)
Revenue: Major Business Units (incl. Forex Impact) (Bn JPY) FY2017 FY2018 Q3 YTD Q3 YTD YoY Results Results Japan 418.1 395.7 -22.4 Daiichi Sankyo Healthcare 56.6 52.9 -3.6 Daiichi Sankyo, Inc. 64.1 28.6 -35.5 Olmesartan 17.4 7.9 -9.4 Welchol 29.3 11.0 -18.3 Effient 10.1 2.4 -7.7 Savaysa 1.6 1.6 +0.
Slide 11: Revenue: Major Products in Japan
Revenue: Major Products in Japan (Bn JPY) FY2017 FY2018 Q3 YTD Q3 YTD YoY Results Results Nexium ulcer treatment 70.0 61.0 -9.0 Lixiana anticoagulant 34.7 49.3 +14.6 Alzheimer’s disease Memary treatment 38.1 39.5 +1.4 Loxonin anti-inflammatory analgesic 29.0 24.3 -4.7 treatment for osteoporosis/ Pra
Slide 12: Edoxaban
eee pase Edoxaban 12
Slide 13: Lixiana: Growth in Japan
Lixiana: Growth in Japan Sales Lixiana reached No.1 sales share at FY2018 Q3 (%) 50 40 31.9% 30 30.9% 20 Lixiana Product A 10 Product B Product C 0 Copyright © 2019 IQVIA. Calculated based on JPM FY2014 Q1 - FY2018 Q3 Reprinted with permission 13
Slide 14: Edoxaban: Growth in Each Country
Edoxaban: Growth in Each Country Volume Steady growth in each country Approved in China (Dec. 2018) 30% 26.0% S. Korea 25% 25.4% Japan 20% 15.3% Taiwan 14.4% Belgium 15% 13.8% Germany 11.4% Italy 10% 11.0% Spain 5% 4.9% UK 0.3% USA 0% Brazil: Launched in Aug. 2018 Copyright © 2019 IQVIA. China:
Slide 15: Regional Value
eee pase Regional Value 15
Slide 16: Regional Value Products
Regional Value Products Aim to have enriched ”regional value products” aligned with regional business strategy in addition to ”global products” such as edoxaban and new oncology products toward 2025 Vision 16
Slide 17: Enrichment of Regional Value Products
Enrichment of Regional Value Products Global products:Edoxaban, oncology, etc. Europe North Japan America ASCA* bempedoic acid & combination tablet Nexium Injectafer Cravit Memary Venofer Asmeton Pralia Movantik Ranmark Tenelia Tarlige Minnebro Vimpat New products *ASCA: Asia, South & Central Americ
Slide 18: Japan: New Products Approval and Additional Approval for Existing Products
Japan: New Products Approval and Additional Approval for Existing Products Tarlige (mirogabalin): Approved in Jan. 2019 MOA: α2δ ligand Indication: peripheral neuropathic pain Minnebro (esaxerenone): Approved in Jan. 2019 MOA: mineralocorticoid blocker Indication: hypertension Vimpat (
Slide 19: Europe: In-licensed LDL-C Lowering Drug
Europe: In-licensed LDL-C Lowering Drug Originator: Esperion Therapeutics, Inc. Licensing Agreement bempedoic acid and bempedoic acid / ezetimibe combination tablet MOA : ACL (ATP citrate lyase) inhibitor (First-in-class) Route, dosage : Oral, once-daily Territory : Europe Role and res
Slide 20: Optimizing Supply Chain
Optimizing Supply Chain 20
Slide 21: Optimizing SC
Optimizing SC Future oriented SC structure transformation Future Multiple, smaller volume Transformation medicines Until now Large molecule compounds Mass-produced products toward Injectable formulations Small molecule compounds the future Solid formulations FY2015 Transfer of Akita Plan
Slide 22: Takatsuki Plant Transfer
Takatsuki Plant Transfer Transferee: Employees: continue to be employed by the transferee Products: continue to be produced and stably supplied at the Takatsuki Plant Transfer Date: Oct. 1st ,2019 Compensation: JPY 37.6 Bn The net assets of the Takatsuki Plant The book value including
Slide 23: Reference: Production Sites (as of Oct. 2019)
Reference: Production Sites (as of Oct. 2019) Japan 13 Sites Formulation Formulation / packaging API / packaging API Daiichi Sankyo Daiichi Sankyo Daiichi Sankyo Chemical Propharma Biotech* Pharma Hiratsuka Onahama Kitamoto Tatebayashi Odawara US/EU/ASCA Formulation Formulation Formulation
Slide 24: R&D Update
eee pase R&D Update 24
Slide 25: R&D Investment Focus and Efficiency
R&D Investment Focus and Efficiency Prioritize projects in order to invest selectively in oncology, especially in ADC & AML/Hem Franchises and Breakthrough Science On-going Clinical studies* Major Projects Invest selectivity JAN 2018 JAN 2019 in oncology, DS-8201 3 9 especially in ADC franchise ADC
Slide 26: List of Compounds for Out-Licensing
List of Compounds for Out-Licensing Accelerate out-licensing activity and choose additional candidates DS-5010 (selective RET inhibitor) Out-licensed to Boston Pharmaceuticals Inc. (AUG 2017) DS-6051 (NTRK/ROS1 inhibitor) Out-licensed to AnHeart (DEC 2018) List of Out-licensing Projects Phas
Slide 27: DS Advancing in Regenerative Medicine / Cell Therapy
DS Advancing in Regenerative Medicine / Cell Therapy Activities within the company until today Strengthen DS RD structure (established Cell Therapy Lab.) Explore compounds through alliances and move forward to commercialization Development Status Program Indications Partners Discovery Pre-clin
Slide 28: Open Innovation Research on iPS-β cell
Open Innovation Research on iPS-β cell Treatments of Type 1 diabetes Insulin injection Islet transplant iPS-β Separate Transplant iPS-β islet only cells by device Liver Pancreas Extract Infuse to liver Alternative treatment to Organ donor Type 1 diabetes patient insulin injection and islet transplan
Slide 29: Next Data Point until ASCO 2019
Next Data Point until ASCO 2019 DS-8201: Decision for early BLA submission in FY2018 Q4~ ASCO 2019 (May 31 ~ June 4, 2019) U3-1402: P1 NSCLC dose escalation part is planned DS-1062: P1 NSCLC dose escalation part is planned Quizartinib: US PDUFA May 25, 2019 29
Slide 30: Appendix
Appendix - R&D Milestone Events - Major R&D Pipeline - Out-licensing Projects - DS-8201 presentation at Scientific Conference - Abbreviations 30
Slide 31: FY2018 R&D Milestone Events
FY2018 R&D Milestone Events As of Jan 2019 FY2018 FY2019 Project Study / Indication Q1 Q2 Q3 Q4 Q1~ P1: multiple tumors Enroll completed P2 pivotal: BC (HER2 positive Post T-DM1) Enroll completed P3: BC (HER2 positive Post T-DM1 vs Phys Choice) Study started P3: BC (HER2 positive vs T-DM1) Study sta
Slide 32: Major R&D Pipeline (Oncology)
Major R&D Pipeline (Oncology) As of Jan 2019 Generic Name/Project Code Number Stage Target indication Region (Class) Phase 1 Phase 2 Phase 3 NDA/BLA BC (HER2 positive post T-DM1) JP/US/EU/Asia ★ BC (HER2 positive vs. T-DM1) JP/US/EU/Asia DS-8201 (Anti-HER2 ADC) BC (HER2 low) JP/US/EU/Asia ADC Franch
Slide 33: Major R&D Pipeline (SM/Vaccine)
Major R&D Pipeline (SM/Vaccine) As of Jan 2019 Stage Generic Name/Project Code Number (Class) Target Indication Region Phase 1 Phase 2 Phase 3 NDA AF ASCA Edoxaban/DU-176b (Fxa inhibitor) VTE ASCA Very elderly patients AF JP Specialty medicine (SM) Prasugrel/CS-747 (anti-platelet agent) Ischemic str
Slide 34: Out-licensing Projects
Out-licensing Projects As of Jan 2019 Pre-clinical Phase 1 Phase 2 PLX7486 (Solid tumor / FMS/TRK inhibitor) PLX8394 (Solid tumor / BRAF inhibitor) Oncology PLX9486 (Solid tumor (gastrointestinal stromal tumor) / KIT inhibitor) DS-1515 DS-2969 Laninamivir (Inflammatory disease / PI3Kδ in
Slide 35: DS-8201: Poster at SABCS Efficacy comparison of 5.4・6.4mg/kg
DS-8201: Poster at SABCS Efficacy comparison of 5.4・6.4mg/kg P1 Study: Best Percent Change in HER2- positive Breast Tumor Size from Baseline as Model-projected Event Rates for DS-8201 of April 18, 2018 Doses of 5.4 and 6.4 mg/kg ORR:52.6%(20/38) PFS:NR ORR:55.7%(34/61) PFS:16.4 M Based on the predic
Slide 36: Abbreviations
Abbreviations Abbreviation BTD Breakthrough therapy designation CR Complete response DCR Disease control rate DLT Dose limiting toxicity DOR Duration of response EGFR Epidermal growth factor receptor MTD Maximum tolerated dose NSCLC Non-small-cell lung cancer ORR Overall response rate Objective resp
Slide 37: Contact address regarding this material
Contact address regarding this material Daiichi Sankyo Co., Ltd. Corporate Communications Department TEL: +81-3-6225-1126 Email: [email protected]
Daiichi Sankyo Company — Q3 FY2018 Earnings Presentation on 6ix